BACKGROUND. An earlier trial of raloxifene, conducted in women with metastatic breast carcinoma who initially had responded to tamoxifen and subsequently developed disease progression, suggested no antitumor activity for raloxifene in tamoxifen-refractory disease. However, preclinical studies and pr
Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma
โ Scribed by Bruce E. Hillner; Davide Radice
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 80 KB
- Volume
- 91
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
medullary recurrence in certain ethnic groups will be the field have read the article. I agree that there is no proof that all-trans retinoic acid (ATRA) therapy confirmed by further observation and analysis of recurrence in the large cooperative group studying APL. predisposes patients to the deve
## BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when adminis